NCT06932146View on ClinicalTrials.gov

A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

March 23, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Kidney Stones

Interventions

DRUG

LLX-424

Tablets for oral administration

Trial Locations (3)

55114

Clinical Research Site #2, Saint Paul

65802

Clinical Research Site #3, Springfield

78217

Clinical Research Site #1, San Antonio

Sponsors

Lead Sponsor

Lilac Therapeutics, Inc.

All Listed Sponsors

lead

Lilac Therapeutics, Inc.

INDUSTRY

NCT06932146 - A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones | Biotech Hunter | Biotech Hunter